Case Report Open Access
Copyright ©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2007; 13(12): 1879-1882
Published online Mar 28, 2007. doi: 10.3748/wjg.v13.i12.1879
Unusual causes of intrahepatic cholestatic liver disease
Elias E Mazokopakis, John A Papadakis, Diamantis P Kofteridis, Department of Internal Medicine, University Hospital of Heraklion Crete, Greece
Elias E Mazokopakis, Department of Internal Medicine, Naval Hospital of Crete, Greece
Author contributions: All authors contributed equally to the work.
Correspondence to: Elias Mazokopakis, MD, PhD, Department of Internal Medicine, University Hospital of Heraklion Crete, Iroon Polytechniu 38A, Chania 73 132, Crete, Greece. elmazokopakis@yahoo.gr
Telephone: +30-282-1082754 Fax: +30-282-1089307
Received: December 13, 2006
Revised: December 17, 2006
Accepted: January 4, 2007
Published online: March 28, 2007

Abstract

We report five cases with unusual causes of intrahepatic cholestasis, including consumption of Teucrium polium (family Lamiaceae) in the form of tea, Stauffer’s syndrome, treatment with tamoxifen citrate for breast cancer, infection with Coxiella Burnetii (acute Q fever), and infection with Brucella melitensis (acute brucellosis).

Key Words: Brucella melitensis, Coxiella Burnetii, Cholestasis, Hepatitis, Stauffer’s syndrome, Tamoxifen, Teucrium polium



INTRODUCTION

The term "cholestasis" indicates stoppage or stasis of bile. Cholestasis is not a disease but a symptom of many diseases. It is defined as a pathologic state of reduced bile formation or flow. This definition applies more to the experimental situation, where the rates of bile formation and flow can be measured, than to human cholestasis, where neither can be assessed. Therefore, the clinical definition of cholestasis is any condition in which substances normally excreted into bile are retained. The mechanisms of cholestasis can be broadly classified into intrahepatic, where an impairment of bile formation occurs, and extrahepatic, where impedance to bile flow occurs after it is formed[1]. Intrahepatic cholestasis occurs in certain instances of viral, alcoholic, drug-induced, and chronic liver diseases, such as genetic defects[2] (Table 1). Gallstones, bile duct strictures, and tumours are the most frequent causes of extrahepatic (mechanical) bile duct obstruction[2] (Table 1). Cholestatic liver disease is characterised by a predominant elevation of serum alkaline phosphatase and bilirubin, although serum bilirubin may be normal until a late stage of the disease. In this paper we discuss five patients with unusual causes of intrahepatic cholestatic liver disease.

Table 1 Causes of cholestasis[2].
Intrahepatic cholestasisExtrahepatic biliary tract diseases
Primary biliary cirrhosis (PBC)Choledocholithiasis
Primary sclerosing cholangitis (PSC)Bile duct tumours (benign and malignant)
Drugs and toxinsAmpullary tumours (benign and malignant)
SepsisPancreatic carcinoma
MalignancyMirizzi’s syndrome
Granulomatous liver disease (infections, chemicals, drugs, miscellaneous)AIDS cholangiopathy
Intrahepatic cholestasis of pregnancyParasites
Hepatitis (viral and alcoholic)PSC (primary sclerosing cholangitis) (see left)
Genetic disorders
Total parenteral nutrition associated cholestasis
Graft versus host disease
Post liver transplant cholestasis
CASES REPORT

We retrospectively studied the case notes of 100 patients with intrahepatic cholestatic liver disease who were hospitalised in two divisions of internal medicine for investigation in 2002-2004. Five unusual causes of intrahepatic cholestasis were revealed in our patients. The causes of intrahepatic cholestasis were defined as unusual with a prevalence < 10%. The medical histories of five representative patients with these causes of cholestasis are reported below:

Case 1

A 67-year old man was admitted to hospital for a 5-d history of painless jaundice, pruritus, dark urine and light stools. His medical history included fatty liver, associated with hyperlipidemia and the consumption of ethanol, which was confirmed by an abdominal ultrasound scan and liver biopsy performed in the previous year. Consumption of Teucrium polium (family Lamiaceae) in the form of tea for the treatment of hyperlipidemia during the previous 6 mo (increasing to 2 litres per day in the preceding month) was also mentioned. Physical examination revealed yellow pigmentation of the sclera and skin. Laboratory tests showed the following values: haematocrit (Ht) 46%, white blood cell (WBC) count 7000 cells/mm3 (neutrophils 53%, lymphocytes 29.3%, monocytes 10.2%, eosinophils 6.6%), MCV106 fL (normal range: 80-99 fL), platelet (PLT) count 1330000/mm3 (normal range: 1500000-4500000/mm3), international normalized ratio (INR) 2.9 (normal value: < 1.7), alanine aminotransferase (ALT) 1272 U/L (normal range: 5-40 U/L), aspartate aminotransferase (AST) 1739 U/L (normal range: 5-40 U/L), γ-glutamyl transpeptidase (GGT) 302 U/L (normal range: 10-75 U/L), alkaline phosphatase (ALP) 190 U/L (normal range: 35-125 U/L), total bilirubin (Bil) 11.37 mg/dL (normal range: 0.1-1.3 mg/dL), direct-bilirubin (d-Bil) 7.97 mg/dL, albumin (Alb) 3.3 gr/dL (normal range: 3.5-5.0 g/dL), lactate dehydrogenase (LDH) 380 U/L (normal range: 80-230 U/L), bilirubin and urobilinogen in the urine. Serological and immunologic tests, such as tests for hepatotropic viruses were negative. Histopathology of a liver biopsy revealed cholestatic hepatitis compatible with drug-induced hepatitis. The management of the patient was successful mainly consisted of careful parenteral administration of suitable fluids and vitamin K, per os administration ursodeoxycholic acid and a frequent assessment of the liver function tests. Liver dysfunction was restored one month after his admission.

Final diagnosis: Acute cholestatic hepatitis caused by Teucrium polium L.

Case 2

A 50-year old man [farmer, smoker (40 packs/year)] was admitted to hospital because of a 5-d history of high-grade intermittent fever (up to 38.5°C) associated with mild left abdominal pain, fatigue, and anorexia. Weight loss (approximately 12 kg) during the previous two months was also mentioned. His medical history included Hashimoto thyroiditis and vitiligo. Physical examination revealed a palpable abdominal mass on the left kidney that was confirmed by ultrasound and CT scans of the abdomen. Laboratory tests showed the following values: Ht 31%, WBC 9000 cells/mm3 (neutrophils 53%, lymphocytes 27%, monocytes 13%, eosinophils 7%), PLT 4700000/mm3, erythrocyte sedimentation rate (ESR) 140 mm/h, C-reactive protein (CRP) 8 mg/dL (normal range: 0.08-0.8 mg/dL), ALT 260 U/L, AST 227 U/L, GGT 140 U/L, ALP 187 U/L, Bil 2.1 mg/dL, d-Bil 1.8 mg/dL, Alb 3.2 gr/dL, LDH 370 U/L, INR 2.9, microscopic haematuria in urinalysis. Serological and immunologic tests were negative. A left radical nephrectomy was performed. Pathologic examination revealed stage0II renal cell carcinoma (RCC). Six weeks after the nephrectomy, the liver function tests, the ESR and CRP level were normal. There was no recurrence or metastasis throughout the 3-year follow-up period.

Final diagnosis: Non-metastatic cholestatic paraneo-plastic syndrome associated with RCC stage0II (Stauffer’s syndrome).

Case 3

A 60-year old woman was admitted to hospital for the check of elevated liver function test levels in blood examinations. Her medical history included fatty liver confirmed by an abdominal ultrasound scan and liver biopsy performed in the previous year (steatohepatitis). She had a previous history of modified mastectomy with axillary lymphadenectomy for a retroareolar, canalicular breast carcinoma 6 months ago. She received adjuvant radiation and started tamoxifen citrate (20 mg daily) two months before admission. Physical examination revealed hepatomegaly that was confirmed by an abdominal ultrasound and CT scan. No hepatic metastasis or main bile duct obstruction was detected. Laboratory tests showed the following values: Ht 43%, WBC 7600 cells/mm3 (neutrophils 60%, lymphocytes 28%, monocytes 8%, eosinophils 4%), MCV 102 fl, PLT 1420000/mm3, INR 1.9, ALT 377 U/L, AST 284 U/L, GGT 342 U/L, ALP 290 U/L, Bil 1.5 mg/dL, d-Bil 1.2 mg/dL, Alb 3.2 gr/dL, LDH 320 U/L. Serological and immunologic tests, tumour markers, such as tests for hepatotropic viruses were also negative. Histopathology of a liver biopsy revealed cholestatic hepatitis compatible with drug-induced hepatitis. Tamoxifen was withdrawn and methylprednisolone (1 g daily) was administered for 3 d. Thereafter, 0.5 mg/kg prednisone was indicated for 7 d and subsequently decreased. Five weeks after the discontinuation of tamoxifen citrate, serum ALP and GGT levels were normalized, while serum ALT and AST concentrations were approximately a little above the normal limits. Currently she is receiving anastrazole (aromatase inhibitor).

Final diagnosis: Acute cholestatic hepatitis caused by Tamoxifen citrate.

Case 4

A 39-year old man presented with a one-month history of painless jaundice and after a 5-day period of dark urine without fever. His personal and family medical history was unremarkable. Physical examination revealed yellow pigmentation of the sclera and skin. Laboratory tests showed the following values: Ht 47%, WBC 6700 cells/mm3, PLT 2150000/mm3, ALT 762 U/L, AST 735 U/L, GGT 167 U/L, ALP 417 U/L, Bil 3.19 mg/dL, d-Bil 2.15 mg/dL, LDH 390 U/L, urobilinogen in the urine. Immunologic tests, such as tests for hepatotropic viruses were negative. A four-fold increase was found by comparing the titers of IgG antibodies to phaseII antigen of Coxiella Burnetii in two consecutive assays (indirect immunofluorescence antibody technique, IFAT). Histopathology of a liver biopsy revealed acute hepatitis. The patient was treated successfully with doxycycline (100 mg per os twice daily) for 2 wk. Liver dysfunction was restored two months after his admission.

Final diagnosis: Acute cholestatic hepatitis caused by Coxiella Burnetii (acute Q fever infection).

Case 5

A 47-year old man shepherd was admitted to hospital, because of a 2-wk period of intermittent low-grade fever, fatigue, malodorous sweating and headache. His personal and family medical history was unremarkable. A record of the consumption of unpasteurised dairy products during the previous months was reported. Physical examination revealed hepatomegaly that was confirmed by an abdominal ultrasound scan. Laboratory tests showed the following values: Ht 36, WBC 7900 cells/mm3 (neutrophils 60%, lymphocytes 30%, monocytes 7%, eosinophils 3%), PLT 1230000/mm3, ESR 53 mm/h, CRP 4.43 mg/dL, ALT 672 U/L, AST 769 U/L, GGT 432 U/L, ALP 342 U/L, Bil 2.3 mg/dL, d-Bil 2 mg/dL, Alb 3.3 gr/dL, LDH 380 U/L. Brucella agglutinin titter was positive at 1/320 and growth of Brucella melitensis in blood culture after 5 d. After a putative diagnosis of brucellosis, the patient was administered doxycycline (100 mg per os twice daily) for six weeks plus 1 g streptomycin im for the first 21 d, beginning on the third day of hospitalisation, while waiting the serological and cultural confirmation. Liver dysfunction was restored five weeks after his admission.

Final diagnosis: Acute cholestatic hepatitis caused by Brucella melitensis.

DISCUSSION
Case 1

The final diagnosis was based on the excessive consum-ption of Teucrium polium tea during the month before admission, and the exclusion of other cholestatic syn-dromes. The histopathological change in the findings of the liver biopsy, taken before and after the consumption of the excessive amount of tea was also conclusive evidence of the cause of cholestatic hepatitis. Although the mechanism of Teucrium polium hepatotoxicity is unclear, teucrin A and several neoclerodane diterpenoids, present in the aerial parts of the plant, have been reported as the probable hepatotoxic precursors of this herb[3]. In some instances, liver injury has been associated with the presence of autoantibodies in the serum[4,5]. It has also been reported that some flavonoids have antihyperlipidemic properties, while some terpenoids could inhibit lipid peroxidation[3]. In 1995 Mattei et al[6] reported massive hepatocyte necrosis predominantly in the centrilobular areas of the liver in a patient with acute liver failure after the consumption of Teucrium polium.

Case 2

Stauffer’s syndrome is a non-metastatic cholestatic pa-raneoplastic syndrome usually associated with RCC, with an incidence of 3%-6% among these patients[7,8]. The syndrome is also associated with other malignancies, such as bronchial adenocarcinoma, leiomyosarcoma and prostate adenocarcinoma[9-11]. Stauffer’s syndrome may result from tumour production of cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and possibly interleukin-6 (IL-6)[12,13]. Nephrectomy may result in the amelioration of hepatic dysfunction, but persistent or recurrent elevations may herald local recurrence or metastatic disease[14]. It is remarkable that RCC was an unexpected finding diagnosed during the investigation of systemic symptoms and hepatic dysfunction in our patient. The hepatic dysfunction was returned to normal after nephrectomy.

Case 3

Tamoxifen is a synthetic antioestrogen with both agonist and antagonist properties and plays an important role in prevention and treatment of breast cancer[15]. It is believed to act primarily through binding to oestrogen receptors in breast cancer cells, acting as a competitive inhibitor of oestrogen. Several forms of drug-induced liver disease, such as clolestasis, benign liver tumours, hepatocellular carcinoma, acute hepatitis, submassive hepatic necrosis, steatosis, and steatohepatitis, have been attributed to tamoxifen[15,16]. Although tamoxifen is a known cause of cholestasis, very little attention has been focused on its use in patients with pre-existing liver dysfunction and the possible need for dose adjustment[17]. The pre-existing steatohepatitis might contribute to the early development of tamoxifen-induced cholestasis (2 mo after tamoxifen administration) in our patient.

Case 4

The final diagnosis was based on both serological and clinical criteria. Coxiella Burnetii has a worldwide distribution and reports from various countries show a variety of clinical and epidemiological features of Q fever from one area of the world to another[18]. Hepatic involvement is frequent in Greece as well as in France where it accounts for approximately 40%-50% of acute cases[19,20]. Usually hepatic involvement is asymptomatic with a mild increase (2-3 times the normal level) of ALP, AST, and ALT[21]. Jaundice is a rare finding in Q fever hepatitis while hepatomegaly is quite common[20]. The three clinical presentations of Q fever hepatitis are infectious viral-like hepatitis, fever of unknown origin with granulomatous hepatitis, and incidental finding of elevated transaminases in a patient with pneumonia. In patients with granulomatous hepatitis liver biopsy shows a typical doughnut granuloma with dense fibrin ring surrounded by a central lipid vacuole, that is highly suggestive of the disease caused by Coxiella burnetii[21,22]. Extensive destruction of liver tissue leading to hepatic coma and death have occasionally been reported[23,24].

Case 5

Brucellosis, a world-wide zoonotic disease, is a systemic infection caused by facultative intracellular bacteria of the genus Brucella that can involve many organs and tissues[25]. Brucellosis is a major public health concern in Greece, especially in areas where animal breeding is an important economic resource. Brucella melitensis is the most pathogenic and invasive species of Brucella and occurs more frequently in general human population than in other known species. Hepatic tenderness and mild elevation of transaminases and ALP may be found in acute disease[26]. Asymptomatic, mild cholestatic hepatitis accounted for approximately 16% of acute cases of brucellosis in a small study from Greece[27].

CONCLUSION

In conclusion, use of herbal remedies, as Teucrium polium must be considered a possible aetiology in the setting of clinical and/or biochemical manifestations of liver injury, since alternative medicine and herbal treatments have growing appeal to many societies. Malignant diseases including hypernephroma, treatment with tamoxifen citrate, and infections with Coxiella Burnetii or Brucella melitensis are also unusual causes of cholestatic hepatitis. Clinicians should consider these causes during diagnostic workup of intrahepatic cholestatic liver disease.

Footnotes

S- Editor Wang J L- Editor Wang XL E- Editor Liu Y

References
1.  Sherlock S, Dooley J. a) Jaundice, b) Cholestasis. Diseases of the Liver and Biliary System. 9th ed. Oxford: Blackwell Scientific Publ 1993; 199-213, 214-236.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Barnes DS. Intrahepatic cholestatic liver disease. The Cleveland Clinic Disease Management Project. July 2, 2002.  Available from: http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic.htm..  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Mazokopakis E, Lazaridou S, Tzardi M, Mixaki J, Diamantis I, Ganotakis E. Acute cholestatic hepatitis caused by Teucrium polium L. Phytomedicine. 2004;11:83-84.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 23]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
4.  Polymeros D, Kamberoglou D, Tzias V. Acute cholestatic hepatitis caused by Teucrium polium (golden germander) with transient appearance of antimitochondrial antibody. J Clin Gastroenterol. 2002;34:100-101.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 38]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
5.  Starakis I, Siagris D, Leonidou L, Mazokopakis E, Tsamandas A, Karatza C. Hepatitis caused by the herbal remedy Teucrium polium L. Eur J Gastroenterol Hepatol. 2006;18:681-683.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 33]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
6.  Mattéi A, Rucay P, Samuel D, Feray C, Reynes M, Bismuth H. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J Hepatol. 1995;22:597.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 54]  [Cited by in F6Publishing: 59]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
7.  MoDougal WS, Garnick MB. Clinical signs and symptoms of renal cell carcinoma. Comprehensive Textbook of Genitourinary Oncology, 2nd ed. Philadelphia: Lippincott, Williams, and Wilkins 2000; 112.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Dourakis SP, Sinani C, Deutsch M, Dimitriadou E, Hadziyannis SJ. Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol. 1997;9:311-314.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 33]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
9.  Saintigny P, Spano JP, Tcherakian F, Pailler MC, Breau JL. Non-metastatic intrahepatic cholestasis associated with bronchial adenocarcinoma. Ann Med Interne (Paris). 2003;154:171-175.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Fraisse TC, Damigny A, di Castri A, de Wazières B, Fourcade J. Leiomyosarcoma and Stauffer syndrome. Rev Med Interne. 2001;22:1116-1118.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 5]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
11.  Karakolios A, Kasapis C, Kallinikidis T, Kalpidis P, Grigoriadis N. Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol. 2003;1:480-483.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 39]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
12.  Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer. 1997;72:424-430.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 2]  [Reference Citation Analysis (0)]
13.  Muñoz Vélez D, Rebasa Llull M, Hidalgo Pardo F, Riera Marí V, Mus Malleu A, Gutiérrez Sanz-Gadea C, Ozonas Moragues M. Etiopathogenesis and management of paraneoplastic fever and Stauffer syndrome in renal carcinoma. Actas Urol Esp. 1999;23:379-383.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Chuang YC, Lin AT, Chen KK, Chang YH, Chen MT, Chang LS. Paraneoplastic elevation of serum alkaline phosphatase in renal cell carcinoma: incidence and implication on prognosis. J Urol. 1997;158:1684-1687.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 34]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
15.  Farrell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002;22:185-194.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 150]  [Cited by in F6Publishing: 160]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
16.  Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis. 2001;12:113-124.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg KA. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Ann Oncol. 1998;9:1123-1126.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 72]  [Reference Citation Analysis (1)]
18.  Kofteridis DP, Mazokopakis EE, Tselentis Y, Gikas A. Neurological complications of acute Q fever infection. Eur J Epidemiol. 2004;19:1051-1054.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 25]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
19.  Tselentis Y, Gikas A, Kofteridis D, Kyriakakis E, Lydataki N, Bouros D, Tsaparas N. Q fever in the Greek Island of Crete: epidemiologic, clinical, and therapeutic data from 98 cases. Clin Infect Dis. 1995;20:1311-1316.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 44]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
20.  Raoult D, Tissot-Dupont H, Foucault C, Gouvernet J, Fournier PE, Bernit E, Stein A, Nesri M, Harle JR, Weiller PJ. Q fever 1985-1998. Clinical and epidemiologic features of 1,383 infections. Medicine (Baltimore). 2000;79:109-123.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 388]  [Cited by in F6Publishing: 352]  [Article Influence: 14.7]  [Reference Citation Analysis (0)]
21.  Domingo P, Orobitg J, Colomina J, Alvarez E, Cadafalch J. Liver involvement in acute Q fever. Chest. 1988;94:895-896.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 7]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
22.  Spelman DW. Q fever: a study of 111 consecutive cases. Med J Aust. 1982;1:547-58, 551, 553.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Berkovitch M, Aladjem M, Beer S, Cohar K. A fatal case of Q fever hepatitis in a child. Helv Paediatr Acta. 1985;40:87-91.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Derrick EH. The course of infection with Coxiella burneti. Med J Aust. 1973;1:1051-1057.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Mazokopakis E, Christias E, Kofteridis D. Acute brucellosis presenting with erythema nodosum. Eur J Epidemiol. 2003;18:913-915.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 7]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
26.  Cervantes F, Bruguera M, Carbonell J, Force L, Webb S. Liver disease in brucellosis. A clinical and pathological study of 40 cases. Postgrad Med J. 1982;58:346-350.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 73]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
27.  Kofteridis D, Milaki G, Alegakis D, Mazokopakis E, Christias E, Samonis G. Human brucellosis in Crete, Greece. Poster 580. Clin Microbiol Infect. 2005;11:159.  [PubMed]  [DOI]  [Cited in This Article: ]